Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 123

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 123
---
 as follows (in thousands except share and per share data):

12

Number of UnitsWeighted Average Grant-Date Fair ValueOutstanding RSU awards as of December 31, 2024— $— Granted898,175 10.56 Vested— — Forfeited(15,400)10.56 Outstanding RSU awards as of March 31, 2025882,775 $10.56 As of March 31, 2025, there was approximately $9.0 million of unrecognized stock-based compensation expense related to RSU awards that is expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.93 years. The aggregate fair value of RSU awards that vested during the three months ended March 31, 2025 and 2024 was zero and zero, respectively.Stock OptionsA summary of option activity during the three months ended March 31, 2025 is as follows (in thousands except share and per share data):NUMBER OF OPTIONSWEIGHTED-AVERAGE EXERCISE PRICEOutstanding as of December 31, 20245,384,760 $42.19 Granted— — Exercised(7,342)0.48 Cancelled or Forfeited (37,776)58.67 Expired— $— Outstanding as of March 31, 20255,339,642 $42.13 Options exercisable as of March 31, 20253,309,432 $35.27 The summary of option activity includes performance-based stock options granted during 2024. As of March 31, 2025, there has been no expense recognized for the performance-based stock options. The weighted-average grant date fair value price per share of options granted during the three months ended March 31, 2025 and 2024 was $0.00 and $40.72, respectively. As of March 31, 2025, there was $72.0 million of unrecognized stock-based compensation expense related to unvested stock options, including $4.9 million of unrecognized stock-based compensation expense related to unvested performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 2.27 years. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company